University of Michigan spinout company Courage Therapeutics, which is developing medications for eating disorders and obesity, has received a seed investment of up to $7.8 million from Arsenal Bridge Ventures.
The investment will enable Courage Therapeutics to complete essential testing and development to advance its drug candidates to clinical trials. The company’s two drug-development programs aim to address obesity and restrictive eating disorders, such as anorexia nervosa and cachexia, by targeting neural circuits in the brain known as the central melanocortin system.